The Society of Urologic Oncology's 2018 Huggins Medal awarded to Dr. Gleave

Date Posted: 
2018-11-29

The Society of Urologic Oncology (SUO) awarded the 2018 Huggins Medal to Dr. Martin Gleave. The medal is presented in recognition by the SUO of a major contribution and/or lifetime achievement in research and/or clinical practice that has contributed to the progress in the treatment for patients with genitourinary neoplasms. It has been awarded annually since 2001.

The Huggins Medal is named after Charles B. Huggins, MD, who was awarded the Nobel Prize for Physiology or Medicine in 1966 in recognition of his work on the hormonal treatment of prostate cancer. The Society of Urologic Oncology's mission is to enable qualified members primarily interested in the care of patients with malignant genitourinary diseases to meet for the purpose of discussion, development, and implementation of ideas to improve care.

Dr. Gleave received the medal and presented the corresponding Huggins lecture, "Targeting the Adaptive Molecular Landscape of Castration-Resistant Prostate Cancer", at the SUO’s 2018 Annual Meeting on November 29, 2018.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development